American and French firm now have expanded roster of clients in the U.S., Europe, and Asia.
Cell Trends and Texcell are combining their offerings to provide biotherapeutic safety testing services. Cell Trends, a Maryland-based CRO, specializes in cell culture and viral clearance testing services. Texcell is a French CRO that provides viral safety and immunology services.
Both companies will now be able to offer the same range of services to its customers in the U.S., Europe, and Asia. The firms report having annual revenues in excess of $8–9 million in virology and cell culture services and a staff of more than 50 people.
“Texcell is currently expanding its BSL-2 (biosafety level 2) viral clearance laboratories to offer more space to the customers located in Europe and Asia,” says Bernard Plichon, president and CEO of Texcell. “The partnership with Cell Trends provides a strong opportunity to develop new business relationships with biotech and pharmaceutical companies on both sides of the Atlantic ocean.”
In the U.S., Cell Trends will change its name to TexCell-NA. Nicolas Dumey, vp of viral safety at Texcell, indicates that “new laboratory suites for virology testing will be designed in the Maryland facility to allow additional space for our customers to utilize important new technologies.”
Established in 1991, Cell Trends provides a range of contract laboratory services using tissue culture and virology-based techniques. Texcell, a spin-off company of the Pasteur Institute, is based in Evry Genopole. It has more than 16,000 sq. ft. of offices and BSL2/BSL3 laboratory facilities. The company offers GLP/GMP compliant services for viral safety, mycoplasma testing, and bioanalysis (TK/PK, immunogenicity, biomarkers, and potency).